Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Gland Pharma Limited
EIR
•Gland Pharma Limited•August 25, 2022

Gland Pharma Limited – FDA EIR, Aug 25, 2022

Record Details

An FDA inspection of Gland Pharma Limited, located in Medchal-Malkajgiri District, Hyderabad, India, was conducted from August 22 to August 25, 2022. This inspection focused on medical device Current Good Manufacturing Practices (cGMP) under the Quality System Regulation (21 CFR 820), marking the first time the facility was assessed for medical device compliance, distinct from its previous drug cGMP inspections.The inspection revealed several observations on an FDA Form 483, primarily concerning the absence of fully established design control procedures. Specifically, the firm's processes for defining, documenting, and approving design input requirements were deemed insufficient. Additionally, the quality audit checklist was found lacking in its coverage of comprehensive design control elements, including planning, inputs, outputs, verification, validation, and risk analysis. Deficiencies were also noted in the audit's scope for Corrective and Preventive Action (CAPA) activities, such as implementation verification and information sharing. The company's Quality Risk Management procedure also required better definition for risk identification and the consistent application of fundamental assessment questions.Company management, including the Managing Director/CEO, acknowledged these findings, committed to addressing the noted deficiencies, and assured the FDA of a timely written response outlining their corrective measures.

Company
Gland Pharma Limited
Inspection date
August 25, 2022
Product type
devices
Office
Office of Medical Device and Radiological Health Operations
People
  • Joshua J. Silvestri
  • Srinivas Sadu (recipient)
  • Theresa Broomall (company_representative)
  • Ravi Chandra Madaka N. (company_representative)
  • Venkata Gopalakrishnam Raju Kunaparaju (company_representative)
View Company Profile

ID · 782a11ea-4dcf-4e82-beb1-39459e334adf

Violation Codes9
21 CFR 82021 CFR 21021 CFR 21121 CFR 421 CFR 820.2021 CFR 820.10021 CFR 820.5021 CFR 820.30(a)21 CFR 820.30

Full citation text and observation details available on the Dashboard.

Other documents for Gland Pharma Limited
  • 483 - 2024-07-25July 25, 2024
  • 483 - 2023-07-14July 14, 2023
  • 483 - 2022-08-25August 25, 2022
  • 483 - 2019-05-16May 16, 2019
  • 483 - 2017-02-03February 3, 2017

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gland Pharma Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.